Better Performance of CARs Deprived of the PD-1 Brake
Morales-Kastresana A., Labiano S., Quetglas JI., Melero I.
Abstract Immunotherapies often permit combinations to increase efficacy. Two approaches are currently leading our field: adoptive therapy with T cells transfected with chimeric antigen receptors and monoclonal antibodies blocking the PD-1/PD-L1 (B7-H1) axis. In this issue of Clinical Cancer Research, preclinical evidence for a synergistic combination of such approaches is reported. Clin Cancer Res; 19(20); 5546–8. ©2013 AACR.